Back to Interventions
Substance / Medication

Lanreotide

SNOMED 395765000UMLS C0209211

Overview

Active Ingredient
lanreotide
RxNorm CUI
68092

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Acromegaly
Neuroendocrine tumour
NEN - neuroendocrine neoplasm

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

6 trials linked to this intervention

6
Total Trials
1
Recruiting
2
With Results

Recent Trials

Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients

NCT05701241Phase 4Recruiting270 enrolled

Somatuline Autogel Preference and Health Economy Study

NCT00681187Phase 4Completed26 enrolled

Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR

NCT00216398Phase 4Completed8 enrolled

Somatuline Autogel: Acromegaly Self/Partner Injection Study

NCT00149188Phase 4Completed30 enrolled

Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients

NCT02075606Phase 4Completed50 enrolled
View all 6 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:
The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review.
Michael Michael, Garcia-Carbonero Rocio, Weber Matthias M et al. · Oncologist · 2017
PMID: 28220021Meta-AnalysisFull text (PMC)
A Randomized Trial Evaluating Patient Experience and Preference Between Octreotide Long-Acting Release and Lanreotide for Treatment of Well-Differentiated Neuroendocrine Tumors.
Raj Nitya, Cruz Elizabeth, O'Shaughnessy Sarah et al. · JCO Oncol Pract · 2022
PMID: 35724357RCTFull text (PMC)
Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease.
van Aerts Rene M M, Kievit Wietske, D'Agnolo Hedwig M A et al. · Gastroenterology · 2019
PMID: 31022403RCT
Patient-Reported Symptom Control of Diarrhea and Flushing in Patients with Neuroendocrine Tumors Treated with Lanreotide Depot/Autogel: Results from a Randomized, Placebo-Controlled, Double-Blind and 32-Week Open-Label Study.
Fisher George A, Wolin Edward M, Liyanage Nilani et al. · Oncologist · 2018
PMID: 29038234RCTFull text (PMC)
Adjuvant celecoxib and lanreotide following transarterial chemoembolisation for unresectable hepatocellular carcinoma: a randomized pilot study.
Tong Huan, Wei Bo, Chen Shuang et al. · Oncotarget · 2017
PMID: 28430638RCTFull text (PMC)
Safety and efficacy of different lanreotide doses in the treatment of polycystic liver disease: pooled analysis of individual patient data.
Temmerman F, Gevers T, Ho T A et al. · Aliment Pharmacol Ther · 2013
PMID: 23799922RCT
The long-term outcome of patients with polycystic liver disease treated with lanreotide.
Chrispijn M, Nevens F, Gevers T J G et al. · Aliment Pharmacol Ther · 2012
PMID: 22111942RCT
Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly.
Tutuncu Yasemin, Berker Dilek, Isik Serhat et al. · Pituitary · 2012
PMID: 21863263RCTFull text (PMC)
Preoperative lanreotide treatment improves outcome in patients with acromegaly resulting from invasive pituitary macroadenoma.
Li Z-Q, Quan Z, Tian H-L et al. · J Int Med Res · 2012
PMID: 22613412RCT
Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: a prospective, randomised trial.
Mao Zhi-gang, Zhu Yong-hong, Tang Hai-liang et al. · Eur J Endocrinol · 2010
PMID: 20061334RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Lanreotide (substance)
SNOMED CT
395765000
UMLS CUI
C0209211
RxNorm CUI
68092

Clinical Data

This intervention maps to 3 entities in the Healos knowledge graph.

3
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
6
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.